The document summarizes Singapore's legislative infrastructure and national coordination efforts related to combating counterfeit medical products. Key points include: 1) Singapore's Health Sciences Authority regulates medicines through various acts, but laws currently do not specifically address counterfeit medicines. 2) A new Health Products Act will consolidate laws, include specific definitions and prohibitions against counterfeit health products, and impose heavier penalties. 3) Singapore coordinates with other agencies but faces challenges from differing priorities and lack of medical expertise in other fields. 4) Reported counterfeit medicine cases primarily involve lifestyle drugs obtained through fringe markets rather than mainstream sources.